Trial Profile
A Single Dose Study to Compare the Pharmacokinetics of Two Probe Formulations of MK-1006
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 1006 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 24 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Nov 2009 Planned end date changed from 1 Dec 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.